About the Odronextamab Clinical Development ProgramOdronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback